News Category Global Banking & Finance Reviews
Eleusis Launches Clinical Development of Psychedelic Infusion Therapies for Major Depressive Disorder and Acquires Kalypso Wellness Centers
Eleusis Launches Clinical Development of Psychedelic Infusion Therapies for Major Depressive Disorder and Acquires Kalypso Wellness Centers
Eleusis Ltd, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced the launch of its clinical development of psychedelic infusion therapies and acquisition of Kalypso Wellness Centers (Kalypso), a leading provider of ketamine infusion therapies in the United States. Under the terms of the agreement, Eleusis will acquire Kalypso and its intellectual property in an all-stock transaction.